The introduction of biologic DMARDs into rheumatology has resulted in a substantial
reduction of the burden of many rheumatic diseases. In the slipstream of the success …

The Th17/T-regulatory (Treg) cell imbalance is involved in the occurrence and development
of organ inflammation in systemic lupus erythematosus (SLE). Metabolic pathways can …

Abnormalities in B cells play pivotal roles in the pathogenesis of systemic lupus
erythematosus (SLE) and lupus nephritis (LN). Breach in central and peripheral tolerance …

The mechanistic target of rapamycin (mTOR) is a master regulator of the inflammatory
response in immune and non-immune cells. In immune cells mTOR regulates metabolism to …

Activation of the mechanistic target of rapamycin (mTOR) is a key metabolic checkpoint of
pro-inflammatory T-cell development that contributes to the pathogenesis of autoimmune …

Systemic lupus erythematosus (SLE) is a chronic autoimmune multisystem disease with a
variable presentation and manifestations ranging from mild to severe or even life …

Vascular anomalies represent a diverse group of disorders classified broadly as
malformations or tumors and include the second most common hereditary bleeding disorder …

Objective This study was initiated to evaluate mammalian target of rapamycin (mTOR)
activation in renal tissue of LN patients. Methods This retrospective study included 187 LN …

MicroRNAs (miRs) are non-coding small RNAs that act as epigenetic modulators to regulate
the protein levels of target mRNAs without modifying the genetic sequences. The role of …

Pro-inflammatory immune system development, metabolomic defects, and deregulation of
autophagy play interconnected roles in driving the pathogenesis of systemic lupus …